Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors

Key Inclusion Criteria: * Male and female participants aged ≥18 years * Participants with metastatic CRC or other solid tumors * Evidence of locally recurrent or metastatic disease based on imaging studies within 28 days of cycle 1/day 1 (C1D1) * CRC participants must have had at least one line of standard-of-care therapy and must have progressed on or been intolerant to, or unable to receive, oxaliplatin, irinotecan, and bevacizumab in the advanced/metastatic setting. * Other solid tumor participants must have had all approved standard therapies that are available to the participant, unless contraindicated or intolerable. * Participants must have experienced documented unequivocal progressive disease by either RECIST v1.1 or clinical assessment, or experienced unacceptable toxicity with their prior therapy. * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1 * If receiving radiation therapy, has had a 2-week washout period following completion of the treatment prior to receiving the C1D1 dose and continues to have at least 1 measurable lesion * At least 42 days since prior immunotherapy, including tumor vaccines and checkpoint inhibitors, and at least 21 days since receipt of chimeric antigen receptor therapy or other modified T-cell therapy * Adequate bone marrow, renal, cardiac, and liver function Key Exclusion Criteria: * Participant has a prior history of malignant bowel obstruction requiring hospitalization in the 6 months prior to enrollme…